Results
MT added to BSC is more effective than BSC alone. As in base case scenario data on patient's characteristic and effectiveness are equal for both analyzed subgroups of patients, results on effectiveness are the same for both subgroups. Estimated difference in QALY is statistically significant. Significance was not tested for LYG's difference.
Adding MT to BSC is more expensive than BSC alone. Estimated differences in total costs were statistically significant. However, estimated incremental cost-utility ratios (ICUR) is 4 times less than acceptability threshold.
The results of probabilistic sensitivity analysis have shown that probability of being cost-effectiveness for MT + BSC is 100%. In each of OWSA scenarios ICUR value was below acceptability threshold.
Model Structure
A cost-utility analysis was performed. The model uses a Markov structure and is split into two distinct phases: an acute phase (from stroke onset to 90 days) and rest-of-life phase (spanning from 91 days to death). There are 7 health states based on the modified Rankin Scale (mRS) scores 0 to 6. In acute phase all treatment effect occurs. In base case during each cycle of rest-of-life phase patient can stay in the same health state as in the end of acute phase, die or experienced a recurrent stroke. In case of recurrent stroke the patient re-entered the model from the start (such patient have a mRS score equal to or greater than their mRS before that recurrent stroke). Half cycle correction was applied. • Time horizon was assumed to be a lifetime.
• Acceptability threshold in this analysis was 125 955 PLN.
• Cost and QALYs were discounted with 5.0% and 3.5% discount rates.
• One-way sensitivity analysis (OWSA) and probabilistic sensitivity analysis (PSA) were performed to test robustness of base case results. Patients suitable for IV rt-PA
Conclusions
Treatment of AIS episodes with MT, using a stent retriever, added to BSC is more effective than BSC alone. This implies in a prolongation of expected life-years and significant gain in QALY. Adding MT to BSC is more expensive than BSC alone but as ICUR values are below acceptability threshold such treatment is cost-effective in Polish settings. Patients contraindicated to IV rt-PA
